<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01909778</url>
  </required_header>
  <id_info>
    <org_study_id>1220.15</org_study_id>
    <secondary_id>2007-007776-42</secondary_id>
    <nct_id>NCT01909778</nct_id>
  </id_info>
  <brief_title>Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis</brief_title>
  <official_title>An Open Label Single Dose Phase I Trial of 120 mg and 240 mg BI 201335 Soft Gel Capsules to Study Pharmacokinetic Properties and Safety in Patients With Compensated Liver Cirrhosis in Historical Comparison With 1220.2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This trial was intended to investigate the pharmacokinetics, safety and tolerability of BI
      201335 NA soft-gel capsules in patients with compensated liver cirrhosis, i.e. grade A
      according to Child-Pugh classification (&lt; 7 points).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0-∞</measure>
    <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h (hours) after drug administration on day 1 and day 15</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
    <description>Maximum plasma concentration (Cmax). Individual Cmax values will be directly determined from the plasma concentration time profiles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
    <description>Time at which the maximum plasma concentration occurs (tmax). Individual tmax values will be directly determined from the plasma concentration time profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz</measure>
    <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
    <description>Area under the concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration (AUC0-tz).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
    <description>Elimination half-life (t1/2). The terminal half-life will be calculated from the terminal rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
    <description>Apparent clearance of the analyte in plasma following extravascular administration (CL/F).
The apparent clearance after oral administration will be determined according to the following equation: CL or CL/F=dose/AUC0-∞. (F=absolute bioavailability factor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
    <description>Apparent volume of distribution during the terminal phase (Vz/F) following an extravascular dose (at steady state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo</measure>
    <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
    <description>Mean residence time of the analyte in the body after oral administration (MRTpo).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Tolerability by Investigator</measure>
    <time_frame>Day 6 of period 1 and 2</time_frame>
    <description>The investigator has assessed tolerability based on adverse events and the laboratory evaluation. Tolerability was assessed by the investigator according to the categories 1=&quot;good&quot;, 2=&quot;satisfactory&quot;, 3=&quot;not satisfactory&quot;, and 4=&quot;bad&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG</measure>
    <time_frame>from intake of the second dose Faldaprevir up to 9 days</time_frame>
    <description>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>BI 201335</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 201335 two single oral doses, separated by 14 days washout period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>single oral doses</description>
    <arm_group_label>BI 201335</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with liver cirrhosis, that is histologically proven in a previous liver
             biopsy; possible aetiologies are: cured HCV infection, former alcohol abuse, genetic
             haemochromatosis, non-alcoholic steatohepatitis or others.

          2. Compensated liver disease, as indicated by Prothrombin time or INR prolonged to &lt;1.7 x
             ULN, serum bilirubin &lt; 2 mg/dl, albumin &gt; 3.5 g/dl, no ascites or encephalopathy
             (Child-Pugh grade A, score &lt; 7)

          3. Age 18 years or older

          4. Male patients, or female with documented hysterectomy, ovariectomy or tubal ligation
             OR menopausal female with last menstrual period at least 12 months prior to screening
             OR female of childbearing potential with a negative serum pregnancy test at screening
             and day 1 and willing to ensure consistent and correct contraception

          5. Written informed consent prior to study enrolment which must be consistent with
             international conference on harmonisation ¿ good clinical practice (ICH-GCP) and local
             legislation.

        Exclusion criteria:

          1. Serological evidence of active HBV, HCV or HIV infection (i.e. seropositivity for HBs
             antigen, anti-HIV-1 or -2 antibodies; if anti-HCV antibody positive, patients must
             have documented negative HCV RNA for at least 12 months)

          2. Usage of any drug within 7 days or 5 halftimes, whichever is longer, prior to
             treatment; or the planned usage of a drug during the course of the current study

          3. Usage of any investigational drug within 30 days prior to treatment; or the planned
             usage of an investigational drug during the course of the current study

          4. Decompensated liver disease within past 12 months, as indicated by variceal bleeding,
             ascites, encephalopathy, Prothrombin time or INR prolonged to &gt; 1,7 x ULN, serum
             bilirubin &gt; 2 mg/dl or albumin &lt; 3,5 g/dl (i.e. Child-Pugh grade B)

          5. ALT or AST levels &gt; 5xULN, Alkaline Phosphatase &gt; 2xULN

          6. Liver cirrhosis due to primary or secondary biliary cirrhosis, sclerosing cholangitis,
             vanishing bile duct disease

          7. History of alcohol abuse within the past 3 months

          8. Known hypersensitivity to any content of the study drug

          9. Pregnant or breast feeding females

         10. Females of childbearing potential who are not willing to ensure consistent and correct
             use of condoms and at least one additional medically accepted method of contraception
             (diaphragm with spermicidal substance, cervical caps) or who are unwilling to comply
             to complete abstinence, from the date of screening until 6 months after the last dose
             of study drug

         11. AFP value &gt; 100 ng/ml; if AFP is &gt; 20 and &lt;= 100 ng/ml, patients can be included if
             liver cancer is excluded by two congruent imaging studies (i.e. ultrasound plus CT
             scan or MRI)

         12. Evidence of chronic kidney failure (i.e. serum creatinine &gt; ULN)

         13. Haemoglobinopathy (e.g., thalassaemia major or sickle cell anaemia)

         14. Concomitant intercurrent illnesses including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness or social situation that would limit compliance
             with trial requirement or which are considered relevant for the evaluation of the
             pharmacokinetic parameters or safety of the trial drug.

         15. Active or suspected malignancy or history of malignancy within the last 2 years (with
             the exception of appropriately treated basal cell carcinoma or in situ carcinoma of
             the uterine cervix)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.15.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2013</study_first_submitted>
  <study_first_submitted_qc>July 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <results_first_submitted>July 3, 2015</results_first_submitted>
  <results_first_submitted_qc>August 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2015</results_first_posted>
  <last_update_submitted>August 3, 2015</last_update_submitted>
  <last_update_submitted_qc>August 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>The trial was a nonrandomised, open-label, 2-period fixed-sequence trial to evaluate two single oral doses of Faldaprevir, separated by 14 days washout period. The dose levels were 120 mg first, 240 mg second.
A number of 12 entered patients with compensated liver cirrhosis was planned.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>failed screening</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>While a number of 12 entered patients with non-HCV liver cirrhosis was planned, only a total of 2 patients were enrolled in 1 centre in Germany.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>The trial was a nonrandomised, open-label, 2-period fixed-sequence trial to evaluate two single oral doses of Faldaprevir, separated by 14 days washout period. The dose levels were 120 mg and 240 mg.
A number of 12 entered patients with compensated liver cirrhosis was planned.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC 0-∞</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞).</description>
        <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h (hours) after drug administration on day 1 and day 15</time_frame>
        <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose of Faldaprevir (Period 1)</title>
            <description>single dose of 120 mg Faldaprevir soft gel capsule.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Faldaprevir (Period 2)</title>
            <description>single dose of 240 mg Faldaprevir soft gel capsule after a wash-out period of at least 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC 0-∞</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC 0-∞).</description>
          <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
          <units>h*ng/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7240"/>
                    <measurement group_id="O2" value="24700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum plasma concentration (Cmax). Individual Cmax values will be directly determined from the plasma concentration time profiles.</description>
        <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
        <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose of Faldaprevir (Period 1)</title>
            <description>single dose of 120 mg Faldaprevir soft gel capsule.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Faldaprevir (Period 2)</title>
            <description>single dose of 240 mg Faldaprevir soft gel capsule after a wash-out period of at least 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum plasma concentration (Cmax). Individual Cmax values will be directly determined from the plasma concentration time profiles.</description>
          <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
          <units>ng/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308"/>
                    <measurement group_id="O2" value="999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Time at which the maximum plasma concentration occurs (tmax). Individual tmax values will be directly determined from the plasma concentration time profiles.</description>
        <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
        <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose of Faldaprevir (Period 1)</title>
            <description>single dose of 120 mg Faldaprevir soft gel capsule.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Faldaprevir (Period 2)</title>
            <description>single dose of 240 mg Faldaprevir soft gel capsule after a wash-out period of at least 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time at which the maximum plasma concentration occurs (tmax). Individual tmax values will be directly determined from the plasma concentration time profiles.</description>
          <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
          <units>hours</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00"/>
                    <measurement group_id="O2" value="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz</title>
        <description>Area under the concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration (AUC0-tz).</description>
        <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
        <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose of Faldaprevir (Period 1)</title>
            <description>single dose of 120 mg Faldaprevir soft gel capsule.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Faldaprevir (Period 2)</title>
            <description>single dose of 240 mg Faldaprevir soft gel capsule after a wash-out period of at least 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz</title>
          <description>Area under the concentration-time curve over the time interval from 0 to the last quantifiable plasma concentration (AUC0-tz).</description>
          <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
          <units>h*ng/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6770"/>
                    <measurement group_id="O2" value="23900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2</title>
        <description>Elimination half-life (t1/2). The terminal half-life will be calculated from the terminal rate constant.</description>
        <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
        <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose of Faldaprevir (Period 1)</title>
            <description>single dose of 120 mg Faldaprevir soft gel capsule.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Faldaprevir (Period 2)</title>
            <description>single dose of 240 mg Faldaprevir soft gel capsule after a wash-out period of at least 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>Elimination half-life (t1/2). The terminal half-life will be calculated from the terminal rate constant.</description>
          <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
          <units>hours</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F</title>
        <description>Apparent clearance of the analyte in plasma following extravascular administration (CL/F).
The apparent clearance after oral administration will be determined according to the following equation: CL or CL/F=dose/AUC0-∞. (F=absolute bioavailability factor)</description>
        <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
        <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose of Faldaprevir (Period 1)</title>
            <description>single dose of 120 mg Faldaprevir soft gel capsule.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Faldaprevir (Period 2)</title>
            <description>single dose of 240 mg Faldaprevir soft gel capsule after a wash-out period of at least 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F</title>
          <description>Apparent clearance of the analyte in plasma following extravascular administration (CL/F).
The apparent clearance after oral administration will be determined according to the following equation: CL or CL/F=dose/AUC0-∞. (F=absolute bioavailability factor)</description>
          <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
          <units>mL/min</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F</title>
        <description>Apparent volume of distribution during the terminal phase (Vz/F) following an extravascular dose (at steady state).</description>
        <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
        <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose of Faldaprevir (Period 1)</title>
            <description>single dose of 120 mg Faldaprevir soft gel capsule.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Faldaprevir (Period 2)</title>
            <description>single dose of 240 mg Faldaprevir soft gel capsule after a wash-out period of at least 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F</title>
          <description>Apparent volume of distribution during the terminal phase (Vz/F) following an extravascular dose (at steady state).</description>
          <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
          <units>Liter</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="809"/>
                    <measurement group_id="O2" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRTpo</title>
        <description>Mean residence time of the analyte in the body after oral administration (MRTpo).</description>
        <time_frame>-0:15, 1:00, 2:00, 3:00, 4:00, 5:00, 6:00, 8:00, 12:00, 16:00, 20:00, 24:00, 48:00, 72:00, 96:00, 120:00 h after drug administration on day 1 and day 15</time_frame>
        <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose of Faldaprevir (Period 1)</title>
            <description>single dose of 120 mg Faldaprevir soft gel capsule.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Faldaprevir (Period 2)</title>
            <description>single dose of 240 mg Faldaprevir soft gel capsule after a wash-out period of at least 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>MRTpo</title>
          <description>Mean residence time of the analyte in the body after oral administration (MRTpo).</description>
          <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3">Not calculable as only one participant analysed.</measurement>
                    <measurement group_id="O2" value="31.6">Not calculable as only one participant analysed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Tolerability by Investigator</title>
        <description>The investigator has assessed tolerability based on adverse events and the laboratory evaluation. Tolerability was assessed by the investigator according to the categories 1=“good”, 2=“satisfactory”, 3=“not satisfactory”, and 4=“bad”.</description>
        <time_frame>Day 6 of period 1 and 2</time_frame>
        <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose of Faldaprevir (Period 1)</title>
            <description>single dose of 120 mg Faldaprevir soft gel capsule.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Faldaprevir (Period 2)</title>
            <description>single dose of 240 mg Faldaprevir soft gel capsule after a wash-out period of at least 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Tolerability by Investigator</title>
          <description>The investigator has assessed tolerability based on adverse events and the laboratory evaluation. Tolerability was assessed by the investigator according to the categories 1=“good”, 2=“satisfactory”, 3=“not satisfactory”, and 4=“bad”.</description>
          <population>Only one patient was treated and completed this study; he was the only patient analysed.</population>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG</title>
        <description>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
        <time_frame>from intake of the second dose Faldaprevir up to 9 days</time_frame>
        <population>Only one patient was treated and completed this study; he was the only patient analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose of Faldaprevir (Period 1)</title>
            <description>single dose of 120 mg Faldaprevir soft gel capsule.</description>
          </group>
          <group group_id="O2">
            <title>High Dose of Faldaprevir (Period 2)</title>
            <description>single dose of 240 mg Faldaprevir soft gel capsule after a wash-out period of at least 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG</title>
          <description>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinanalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
          <population>Only one patient was treated and completed this study; he was the only patient analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From intake of the second dose Faldaprevir up to 9 days. Patients were required to report spontaneously any adverse events (AEs) as well as the time of onset, duration and intensity of these events.</time_frame>
      <desc>In addition, each patient was assessed by an investigator at any measurement time point as well as at the end of observation and whenever necessary as deemed by the investigator. Assessment was made using non-specific questions such as “How do you feel?”. Specific questions were asked wherever required or useful to more precisely describe an AE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Dose of Faldaprevir (Period 1)</title>
          <description>single dose of 120 mg Faldaprevir soft gel capsule.</description>
        </group>
        <group group_id="E2">
          <title>High Dose of Faldaprevir (Period 2)</title>
          <description>single dose of 240 mg Faldaprevir soft gel capsule after a wash-out period of at least 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Soft stools</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

